Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbSci (ABSI)
NASDAQ:ABSI
AbSci (ABSI) Stock Price & Analysis
500 Followers
ABSI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.11 - $6.72
Previous Close$3.97
Volume771.59K
Average Volume (3M)1.57M
Market Cap
$453.47M
Enterprise Value$404.36M
Total Cash (Recent Filing)$58.83M
Total Debt (Recent Filing)$14.24M
Price to Earnings (P/E)―
Beta2.88
Next Earnings
Aug 14, 2024EPS Estimate
-$0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding113,083,669
10 Day Avg. Volume2,179,542
30 Day Avg. Volume1,567,185
Standard Deviation0.37
R-Squared0.11
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.77
Price to Sales (P/S)1010.39
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue75.62
Enterprise Value/Gross Profit70.72
Enterprise Value/Ebitda-5.19
Forecast
1Y Price Target
$7.80Price Target Upside94.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
AbSci News
Bulls Say, Bears Say
Bulls Say
Clinical PotentialAbsci reported promising preclinical data from its first clinical candidate ABS-101, demonstrating best-in-class potential for the treatment of inflammatory bowel disease.
Financial StabilityAbsci had approximately $161.5M in cash and cash equivalents, which is believed to be sufficient to support operations into the first half of 2027.
Partnership InterestsABS-101 has generated a lot of partnership interests due to its pre-clinical data and AI-assisted, epitope-specific targeting capability.
Bears Say
EarningsQ1 revenues of $0.9M were well below the Street's expectations of $2.1M.
Financial PerformanceFor 4Q23, Absci reported technology development revenues below consensus estimates and a net loss per share greater than the consensus estimated net loss.
RevenuesFor 4Q23, the company reported technology development revenues of $0.3M, compared to the consensus estimate of $2.2M, and a net loss of $0.25 per share, compared to the consensus estimated net loss of $0.22 per share.
---
Ownership Overview
36.09% Insiders
19.09% Mutual Funds
13.15% Other Institutional Investors
31.66% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $1.11 and its highest was $6.72 in the past 12 months.
What is AbSci’s market cap?
Currently, no data Available
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is Aug 14, 2024 which is in 23 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on May 14, 2024. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -$0.18.
How many shares outstanding does AbSci have?
AbSci has 113,083,670 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
---
AbSci Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.80 (94.51% Upside)
$7.80 (94.51% Upside)
Blogger Sentiment
Bullish
ABSI Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $13.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
65.41%
12-Months-Change
Fundamentals
Return on Equity
-44.20%
Trailing 12-Months
Asset Growth
-7.07%
Trailing 12-Months
Company Description
AbSci
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
---
ABSI Earnings Call
Q1 2024
0:00 / 0:00
---
ABSI Stock 12 Month Forecast
Average Price Target
$7.80
▲(94.51% Upside)
Technical Analysis
Best Analysts Covering ABSI
1 Year
1 Year Success Rate
4/7 ratings generated profit
1 Year Average Return
+108.64%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +108.64% per trade.
---